Key facts
- Verismo Therapeutics’s last known valuation is $93.0M (Jul 2023).
- It has raised $4.0M across 3 recorded rounds; the latest was Early Stage VC ($28.0M) in Apr 2026.
- Notable investors include Institute for Follicular Lymphoma Innovation, ScaleReady.
- Verismo Therapeutics has filed 2 Form Ds with the SEC since 2021, most recently Jul 2023 ($19.2M sold to 7 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Verismo Therapeutics
Funding rounds
3 roundsAbout Verismo Therapeutics
Developer of cancer therapeutics designed to improve persistence and efficacy against solid tumor models. The company specializes in extracting white blood cells from a patient, genetically modifying them to fight specifically against a certain type of cancer, and re-injecting them back into the patient, enabling clinicians to provide natural stimulation to the cells without triggering the T-cell exhaustion.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2020
- Employees
- 29
- Website
- verismotherapeutics.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Verismo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Verismo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Verismo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.